Benefits
Generalized anxiety disorder vs medazepam (pivotal)
An RCT in 62 patients with GAD and neurasthenia compared selank vs medazepam (a benzodiazepine). Anxiolytic effects on Hamilton/Zung/CGI scales were similar for both drugs, but selank additionally showed antiasthenic and psychostimulant effects without medazepam's sedation. Foundational positive RCT supporting Russian approval. Limited by Russian-language literature less accessible to Western reviews.
Anxiety vs phenazepam
A study compared selank vs phenazepam (a Russian benzodiazepine) for anxiety disorders. Selank produced significant improvement in quality of life without noticeable side effects vs phenazepam. Establishes selank as benzodiazepine-comparable anxiolytic with superior tolerability profile.
Rapid responder identification
A study evaluated rapid vs delayed treatment response in 20 GAD patients given selank 2,700 µg/day intranasally. 40% were identified as rapid responders with abrupt symptom reduction in days 1-3 (day 3 HAM-A reduced from 20.3 to 7.0, p<0.01). Rapid responders had more asthenic and cognitive symptoms with higher EEG-reactivity. Important treatment response heterogeneity finding.
GABA-A allosteric modulation
Selank administration alters expression of 45 genes involved in GABAergic neurotransmission in rat frontal cortex within 1 hour. The pattern shows positive correlation with GABA itself, indicating selank functions as an allosteric GABA-A modulator rather than direct agonist. This allosteric mechanism may explain the absence of dependence/withdrawal seen with benzodiazepines (which are direct GABA-A modulators with a different binding profile).
Enkephalin stabilization (anxiolytic mechanism)
Selank inhibits enkephalin-degrading enzymes - extending the duration of endogenous opioid anxiolytic peptides. Mechanism for proposed mood-modulating effects via endogenous opioid system support. Distinct from benzodiazepine mechanism.
Anti-inflammatory effects (clinical observations)
Selank has demonstrated potential to reduce inflammation by inhibiting IL-6 gene activity. Useful for anxiety disorders with comorbid inflammatory features (chronic fatigue, fibromyalgia-like symptoms). Limited rigorous trials but consistent clinical observations across Russian use.
Mechanism of action
Allosteric GABA-A receptor modulation (not direct agonist)
Selank functions as allosteric GABA-A modulator — alters receptor activity through non-active site binding. Distinguishes from benzodiazepines (which are direct GABA-A modulators at the benzodiazepine binding site). Allosteric mechanism may explain absence of dependence, tolerance, sedation, and withdrawal — major advantages over benzodiazepines clinically.
Enkephalin-degrading enzyme inhibition
Inhibits enzymes that break down enkephalin endogenous opioid peptides. Extending enkephalin duration provides anxiolytic and mood-stabilizing effects via endogenous opioid system. Mechanism distinct from exogenous opioid agonists — modulates endogenous tone.
Serotonin metabolism modulation
Animal studies suggest selank affects serotonin metabolism in CNS. Mechanism for proposed mood effects beyond pure GABA modulation. Less clinically validated than GABA-A and enkephalin mechanisms.
Tuftsin-derived immunomodulation
Selank contains tuftsin tetrapeptide N-terminus (Thr-Lys-Pro-Arg) — endogenous immunomodulatory peptide. Inherits some tuftsin properties: phagocyte activation, immune modulation. Mechanism for anti-inflammatory effects observed clinically.
BDNF and gene expression effects
Modulates expression of multiple genes involved in BDNF pathway, glucocorticoid receptors, and stress response. Mechanism for sustained anxiolytic effects beyond acute receptor modulation.
Intranasal BBB penetration
Intranasal administration provides direct CNS access via olfactory and trigeminal nerves — bypassing first-pass hepatic metabolism. Practical advantage of peptide compounds; rapid onset 30-60 minutes.
Clinical trials
Russian-language clinical trial (Zozulia AA, Neznamov GG, Siuniakov TS, Kost NV, Gabaeva MV, Sokolov OIu, Serebriakova EV, Siranchieva OA, Andriushenko AV, Telesheva ES, Siuniakov SA, Smulevich AB, Miasoedov NF, Seredenin SB 2008, Zh Nevrol Psikhiatr Im S S Korsakova 108(4):38-48).
62 patients with generalized anxiety disorder (GAD) and neurasthenia. Selank (n=30) vs medazepam (n=32, benzodiazepine). Hamilton, Zung, CGI psychometric scales. Enkephalin activity in blood serum measured.
Anxiolytic effects of selank and medazepam similar. Selank additionally showed antiasthenic and psychostimulant effects without medazepam's sedation. Clinical-biological study: GAD/neurasthenia patients had decreased τ½ leu-enkephalin correlated with disease duration, anxiety severity, asthenia, autonomic disorders. Selank treatment increased this parameter with stronger positive correlations with anxiety level. Russian-language literature limits Western methodological scrutiny.
Mechanistic study (Zozulya AA, Kost NV, Sokolov OYu, Gabaeva MV, Grivennikov IA, Andreeva LN, Zolotarev YA, Ivanov SV, Andryushchenko AV, Myasoedov NF, Smulevich AB 2001, Bull Exp Biol Med 131(4):315-317, doi:10.1023/a:1017979514274).
Biochemical study of selank effects on enkephalin-degrading enzymes in serum/tissue.
Selank inhibits enkephalin-degrading enzymes — extending duration of endogenous opioid anxiolytic peptides. Foundational mechanism evidence for selank's anxiolytic activity via endogenous opioid system support. Distinct mechanism from benzodiazepine GABA modulation.
Behavioral and gene expression study (Kasian A, Kolomin T, Yatskou M, Myasoedov N, Slominsky P, Behav Neurol 2017:5091027, doi:10.1155/2017/5091027).
Rats in unpredictable chronic mild stress paradigm receiving selank ± diazepam. Frontal cortex transcriptome (45 GABAergic genes) analyzed within 1 hour post-administration.
Selank altered expression of 45 GABAergic genes within 1 hour. Pattern showed positive correlation with GABA itself — indicating selank functions as allosteric GABA-A modulator rather than direct agonist. Selank enhanced diazepam's anxiolytic effect in stress model (synergistic). Foundational mechanistic evidence supporting safety profile (no dependence/withdrawal) vs benzodiazepines.